Akoya Biosciences, Inc. reiterated revenue guidance for the fiscal year 2023. The company, based on its current plans and initiatives, continues to expect full year 2023 revenue in the range of $95-98 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.81 USD | -1.40% | -31.80% | -42.42% |
05-15 | Piper Sandler Cuts Akoya Biosciences Price Target to $6 From $8, Maintains Overweight Rating | MT |
05-14 | Top Midday Decliners | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.42% | 139M | |
+11.91% | 227B | |
+15.46% | 198B | |
+18.58% | 142B | |
+30.36% | 111B | |
+0.65% | 64.16B | |
+17.74% | 54.1B | |
+5.82% | 51.41B | |
+11.23% | 45.32B | |
+5.73% | 37.32B |
- Stock Market
- Equities
- AKYA Stock
- News Akoya Biosciences, Inc.
- Akoya Biosciences, Inc. Reiterates Revenue Guidance for the Fiscal Year 2023